These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Reducing blood pressure and modification of coronary risk factors by therapy with doxazosin].
    Author: Hitzenberger G, Ganzinger U.
    Journal: Wien Klin Wochenschr; 1993; 105(13):371-6. PubMed ID: 8351927.
    Abstract:
    In an open, non-comparative, multicenter trail performed by general practitioners, the efficacy and safety of doxazosin, an inhibitor of postsynaptic alpha 1-adrenoceptors, were studied in 924 patients with mild to moderate hypertension. Under treatment with doxazosin both systolic and diastolic blood pressure decreased significantly from 178.4 +/- 18.2/103.1 +/- 8.6 to 149.1 +/- 12.0/85.6 +/- 7.3 mm Hg; the mean daily dose at the end of the 12 weeks' treatment period was 3.3 +/- 2.6 mg. Heart rate decreased by 5% and body weight by 6%. As compared with baseline values, total cholesterol (255.7 +/- 45.4 vs 232.7 +/- 37.3 mg%), triglycerides (206.3 +/- 97.6 vs 175.2 +/- 70.9 mg%) and blood glucose (101.9 +/- 31.0 vs 97.9 +/- 25.5 mg%) decreased significantly, whilst HDL-cholesterol (47.7 +/- 13.0 vs 51.5 +/- 12.4 mg%) increased. Overall, doxazosin was very well tolerated; only 16% of all patients reported adverse drug reactions. The results of this study confirm the effectiveness of doxazosin as first-line medication in the treatment of hypertension, especially in patients with concomitant metabolic disorders such as hyperlipidemia and diabetes mellitus. Moreover, the patients who appear to benefit most from doxazosin treatment are those who show the highest metabolism-related coronary risk, as calculated according to the Framingham Study equation.
    [Abstract] [Full Text] [Related] [New Search]